(Q37756959)

22 August 2017

1 reference

title

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer (English)

1 reference

22 August 2017

1

Rafael Rosell

1 reference

22 August 2017

Teresa Moran

2

1 reference

22 August 2017

Santiago Viteri

3

1 reference

22 August 2017

Enric Carcereny

4

1 reference

22 August 2017

Amaya Gasco

5

1 reference

22 August 2017

Vanessa Quiroga

6

1 reference

22 August 2017

Jia Wei

7

1 reference

22 August 2017

Carlos Camps

8

1 reference

22 August 2017

Bartomeu Massuti

9

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

1 reference

22 August 2017

11

1 reference

22 August 2017

1683-1693

1 reference

22 August 2017

10

1 reference

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

The DNA damage response: ten years after

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

BRCA1: a novel prognostic factor in resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.482101

10.1517/14656566.2010.482101

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference